COMMUNIQUÉS West-GlobeNewswire

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
13/05/2025
– Announced Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 (tambiciclib) in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) Demonstrating 8.9 mOS in AML-MRC and 8.8 mOS in All r/r [...]
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update
13/05/2025
Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026 Attack dataset continues to accumulate in RAPIDe-3, a pivotal Phase 3 study of [...]
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
13/05/2025
Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual‑targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory large B‑cell [...]
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
13/05/2025
64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL Median duration of [...]
Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
13/05/2025
Revenue grew 37%, driven by increased product sales and service revenue REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new [...]
Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update
13/05/2025
- Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Phase [...]
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
13/05/2025
Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected Q4 2025 CTA [...]
Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update
13/05/2025
Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma [...]
Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer
13/05/2025
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the [...]
Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
13/05/2025
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merger to take place on [...]
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
13/05/2025
Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual Meeting Granted Orphan Drug designation by FDA for TPST-1495 for the treatment of familial [...]
Metagenomi Reports Business Updates and First Quarter 2025 Financial Results
13/05/2025
- Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximate ly 19 months with an encouraging safety profile - Well [...]
Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results
13/05/2025
All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1™ study in obese or overweight individuals; top-line results are [...]
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results
13/05/2025
Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases [...]
Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
13/05/2025
Significant advancements in preclinical pipeline for SIL204, with groundbreaking data demonstrating efficacy against both primary tumors and metastases in orthotopic models; strengthened financial position with over $9 [...]
Scientific Industries Reports Financial Results for First Quarter of Fiscal Year 2025
13/05/2025
BENCHTOP LAB EQUIPMENT SALES UP 5% FIRST PEER-REVIEWED PUBLICATION ON COMPANY’S DOTS MPS BIOPROCESSING PLATFORM RECORD NUMBER OF BIOPROCESSING SALES OPPORTUNITIES Investor Call to be held Wednesday, May 14 th at 11:00 a [...]
Applied Therapeutics Reports First Quarter 2025 Financial Results
13/05/2025
- Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3 trial of govorestat in CMT-SORD Deficiency at the Peripheral Nerve Society 2025 Annual [...]
Claritas Neurocloud™ for Brain Imaging Analysis to Commence Commercialization on Execution of Partnership between Claritas and Qubiotech
13/05/2025
LONDON and SAO PAULO, May 13, 2025 (GLOBE NEWSWIRE) -- Claritas HealthTech Limited (“Claritas”), a healthcare technology company specializing in advanced medical image processing, segmentation, and AI solutions for the [...]
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
13/05/2025
Repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Efforts continue to gain efficiencies through streamlining and cost cutting measures; Company ended the [...]

Pages